posted
Mellow Hope (HTDS) Seminar for Indian Medical Experts to Discuss Cerebroprotein Hydrolysate
Press Release Source: Hard to Treat Diseases, Inc. On Thursday March 3, 2011, 3:45 pm EST SHENZEN, CHINA--(Marketwire - 03/03/11) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (Welcome to HTDS Medical) announced today that its China-based Shenzhen Mellow Hope subsidiary is planning a seminar for Indian medical experts.
The Indian experts are expected in China for the seminar and will visit Chinese medical experts in Beijing, Shanghai and Shenzhen. They will discuss plans to market 'Cognistar' (Cerebroprotein Hydrolysate for Injection) in India. Mellow Hope believes that this product will receive wide acceptance in the Indian market and has huge growth potential.
Mellow Hope finished the clinical trials of Cerebroprotein Hydrolysate for Injection in India. This biological product is a unique nutriment for the brain that helps the central nervous system in multiple ways, including: regulating and improving nerve cell metabolism; promoting synapse generation; inducing nerve cell differentiation; and protecting nerve cells against damages by ischemia and neurotoxins.
Mellow Hope looks forward to the visit from the Indian medical experts and plans to update investors as these developments progress.
IP: Logged |
posted
Mellow Hope (HTDS) Reaches a Milestone in Indonesia
Press Release Source: Hard to Treat Diseases, Inc. On Tuesday March 8, 2011, 3:45 pm EST SHENZEN, CHINA--(Marketwire - 03/08/11) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (Welcome to HTDS Medical) announced that its China-based subsidiary Shenzhen Mellow Hope has been inspected by the Indonesian Muslim Association and been issued a HALAL certificate.
The Indonesian Muslim Association inspected the Mellow Hope plant that produces the ACYW135 and A+C Meningococcal Polysaccharide vaccines. Mellow Hope plant and method of production of these vaccines met the HALAL certificate (Halal Assurance System) requirements. The Indonesian Muslim Association is well-known and regarded as the most authoritative Muslim organization in the world. The HALAL is a difficult certificate to receive, and Mellow Hope believes that there are only two companies in the world that have obtained this certificate.
With the HALAL certificate in hand, Mellow Hope believes that it will have advantage in marketing its MEVAC-ACYW and A+C in Indonesia and other Muslim countries. Mellow Hope is participating in tenders of Group ACYW135 in Indonesia and Bangladesh, and believes that the ability to acquire HALAL certificate will be a great help in securing the tenders.
IP: Logged |
posted
Mellow Hope (HTDS) Increases Indian Vaccine Sales
Email Print Companies:HARD TO TREAT DISEAS Related Quotes Symbol Price Change HTDS.PK 0.00 0.00
Press Release Source: Hard to Treat Diseases, Inc. On Wednesday March 16, 2011, 3:45 pm EDT SHENZHEN, CHINA--(Marketwire - 03/16/11) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS - News) (www.htdsmedical.com) announced that its China-based Shenzhen Mellow Hope subsidiary had a major leap in sales volume for its Hepatitis A (MEVAC-A) vaccine in India in 2010 compared to a year earlier.
Mellow Hope launched the Hepatitis A vaccine in India at the end of 2005, and its high quality and competitive pricing has enabled it to steadily increase its market share year by year. MEVAC-A has been embraced by Indian doctors and patients in need of the vaccine, which has given Mellow Hope a very good reputation in the country.
Mellow Hope believes that it can capitalize on the success and wide acceptance of MEVAC-A and create more business opportunities in India, which should increase profits for HTDS and add value for shareholders.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
